ARCHIVES

Senate Committee Schedules Hearing for FDA Acting Commissioner von Eschenbach.

This article is from The Cancer Letter archive.

Vol. 32 No. 29 | July 28, 2006

Download PDF Visit The Full Archive

Related Articles

No Benefit For Cetuximab In Early-Stage Colon Cancer

December 25, 2009

New Publications

May 4, 1990

NCI To Fund About 4,100 Grants; Increase Planned In Average Costs; Paylines Stable

November 20, 1998

NCI Offers 200 Cell Lines to Scientist

May 6, 1983

FASEB urges 10 percent increase for NIH in FY 2005.

January 23, 2004

HCFA Chief Says Facts Will Not Matter, She Won’t Loosen DRGs For Clinical Trials Unless Congress Orders It

May 4, 1984